Kazia Therapeutics doses first patient in PNOC035 paxalisib AT/RT study
Kazia Therapeutics said the first patient was dosed in its PNOC035 multicenter study evaluating paxalisib plus gemcitabine for recurrent or progressive pediatric AT/RT.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.